Program

Wednesday, September 18

Welcome and Keynote Lectures

6:00 p.m.-8:00 p.m.

Wnt, Lgr5 stem cells, and cancer
Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands

Title to be announced
Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA

Opening Reception

8:00 p.m.-9:30 p.m.

Thursday, September 19

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 1: Transcription and Epigenetics

8:00 a.m.-10:00 a.m.

Title to be announced
Jacqueline A. Lees, MIT Koch Institute for Integrative Cancer Research, Cambridge, MA

Deconstructing p53 pathways in vivo
Laura D. Attardi, Stanford University School of Medicine, Stanford, CA

Chromosomal translocations and transcriptional elongation control in epigenetics and cancer
Ali Shilatifard, Stowers Institute for Medical Research, Kansas City, MO

Break

10:00 a.m.-10:30 a.m.

Plenary Session 2: Post-Transcriptional Regulation

10:30 a.m.-12:30 p.m.

Role of mRNA splicing in cancer
James L. Manley, Columbia University, New York, NY

Translational control of cancer via eIF4E/4E-BPs
Nahum Sonenberg, McGill University, Montreal, QC, Canada

Title to be announced
Davide Ruggero, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Title to be announced
Carol L. Prives, Columbia University, New York, NY

Free Time / Lunch on Own

12:30 p.m.-2:00 p.m.

Plenary Session 3: Noncoding RNAs

2:00 p.m.-4:00 p.m.

Title to be announced
Lin He, University of California, Berkeley, CA

MicroRNAs in oncogenic and tumor suppressor signaling pathways
Joshua Mendell, UT Southwestern Medical Center, Dallas, TX

The noncoding RNA revolution in cancer research
Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Boston, MA

Poster Session A / Reception

4:30 p.m.-7:30 p.m.

Friday, September 20

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 4: Genetic and Functional Heterogeneity

8:00 a.m.-10:00 a.m.

Title to be announced
Luis F. Parada, UT Southwestern Medical Center, Dallas, TX

Heterogeneity in drug sensitivity
Joan S. Brugge, Harvard Medical School, Boston, MA

Intratumour heterogeneity: Deciphering cause and consequence
Charles Swanton, Cancer Research UK, London, United Kingdom

Break

10:00 a.m.-10:30 a.m.

Plenary Session 5: Stress Response, Apoptosis, Autophagy, and Senescence

10:30 a.m.-12:30 p.m.

Hypoxia, metabolism, and tumor progression
M. Celeste Simon, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Role of autophagy in cancer
Eileen P. White, UMDNJ–The Cancer Institute of New Jersey, New Brunswick, NJ

Functions for p53 in the response to stress
Karen H. Vousden, Beatson Institute for Cancer Research, Glasgow, Scotland

Lunch on Own / Free Time

12:30 p.m.-2:00 p.m.

Plenary Session 6: Cancer Microenvironment

2:00 p.m.-4:00 p.m.

Fatty liver disease and the pathogenesis of hepatocellular carcinoma: Role of inflammation and aberrant metabolism
Michael Karin, University of California, San Diego, CA

Microenvironmental forces program tumor progression and aggression
Valerie M. Weaver, UCSF Medical Center, San Francisco, CA

Seeing cancer in context: Insights from live imaging of tumor-stroma interactions
Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Poster Session B / Reception

4:30 p.m.-7:30 p.m.

Saturday, September 21

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 7: Cancer Metabolism

8:00 a.m.-10:00 a.m.

PI3K and cancer metabolism
Lewis C. Cantley, Weill Cornell Medical College of Cornell University, New York, NY

mTOR, metabolism, and cell growth control in cancer
John Blenis, Harvard Medical School, Boston, MA

Title to be announced
Craig B. Thompson, Memorial Sloan-Kettering Cancer Center, New York, NY

Break

10:00 a.m.-10:30 a.m.

Plenary Session 8: Metastasis

10:30 a.m.-12:30 p.m.

Metastasis pathways
Joan Massagué, Memorial Sloan-Kettering Cancer Center, New York, NY

Regulation of metastasis in breast cancer
Zena Werb, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Cell fate determinants as regulators of cancer metastasis
Yibin Kang, Princeton University, Princeton, NJ

Free Time / Lunch on Own

12:30 p.m.-2:00 p.m.

Plenary Session 9: Interpreting the Cancer Genome

2:00 p.m.-4:00 p.m.

Title to be announced
Stephen J. Elledge, Harvard Medical School, Boston, MA

Functional genomics, experimental models, and cancer
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

On the road to personalized therapy, a systems approach
Dana Pe’er, Columbia University, New York, NY

Unraveling mechanisms of tumor suppression in vivo
Scott W. Lowe, Memorial Sloan-Kettering Cancer Center, New York, NY

Poster Session C / Reception

4:30 p.m.-7:30 p.m.

Sunday, September 22

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 10: Signaling I – Cancer Signaling Networks

8:00 a.m.-10:00 a.m.

Targeting cancer cell dependencies on developmental signal transduction pathways
Lawrence Lum, UT Southwestern Medical Center, Dallas, TX

Targeting Ras proteins in human cancer
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Hippo signaling in development and cancer
Duojia Pan, Johns Hopkins Medical Institutes, Baltimore, MD

Title to be announced
Philip A. Beachy, Stanford University, Stanford, CA

Break

10:00 a.m.-10:15 a.m.

Plenary Session 11: Signaling II – Signaling and Drug Resistance

10:15 a.m.-12:15 p.m.

Title to be announced
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY

Title to be announced
Kevan Shokat, University of California, San Francisco, CA

Targeting hyperactive Ras in cancer
Kevin Shannon, University of California, San Francisco, CA